Premium
Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom
Author(s) -
Morris S.,
Ridley S.,
Munro V.,
Christensen M. C.
Publication year - 2007
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.2006.04896.x
Subject(s) - medicine , placebo , cost effectiveness , blunt , recombinant dna , surgery , emergency medicine , risk analysis (engineering) , alternative medicine , pathology , biochemistry , chemistry , gene
Summary The aim of this study was to assess the lifetime cost effectiveness of recombinant activated factor VII vs placebo as adjunctive therapy for control of bleeding in patients with severe blunt trauma in the UK. We developed a cost‐effectiveness model based on patient level data from a 30‐day international, randomised, placebo‐controlled Phase II trial. The data were supplemented with secondary data from UK sources to estimate lifetime costs and benefits. The model produced a baseline estimate of the incremental cost per life year gained with recombinant activated factor VII relative to placebo of £12 613. The incremental cost per quality adjusted life year gained was £18 825. These estimates are sensitive to the choice of discount rate and health state utility values used. Preliminary results suggest that relative to placebo, recombinant activated factor VII may be a cost‐effective therapy to the UK National Health Service.